Inhibitors targeting EZH2, such as EPZ-6438, and GSK126, can reduce H3K27me3 levels, reactivate tumor suppressor genes, and inhibit the growth and metastasis of lung cancer cells. This evidence concerns the gene EZH2 and lung carcinoma.